CL2024000642A1 - Anticuerpos del receptor antitransferrina y usos de los mismos - Google Patents
Anticuerpos del receptor antitransferrina y usos de los mismosInfo
- Publication number
- CL2024000642A1 CL2024000642A1 CL2024000642A CL2024000642A CL2024000642A1 CL 2024000642 A1 CL2024000642 A1 CL 2024000642A1 CL 2024000642 A CL2024000642 A CL 2024000642A CL 2024000642 A CL2024000642 A CL 2024000642A CL 2024000642 A1 CL2024000642 A1 CL 2024000642A1
- Authority
- CL
- Chile
- Prior art keywords
- transferrin receptor
- receptor antibodies
- antibodies
- methods
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239630P | 2021-09-01 | 2021-09-01 | |
| US202263388088P | 2022-07-11 | 2022-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000642A1 true CL2024000642A1 (es) | 2024-09-13 |
Family
ID=83508506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000642A CL2024000642A1 (es) | 2021-09-01 | 2024-03-01 | Anticuerpos del receptor antitransferrina y usos de los mismos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11827702B2 (enExample) |
| EP (1) | EP4396231A1 (enExample) |
| JP (1) | JP2024534880A (enExample) |
| KR (1) | KR20240107202A (enExample) |
| AU (1) | AU2022340568A1 (enExample) |
| CA (1) | CA3230796A1 (enExample) |
| CL (1) | CL2024000642A1 (enExample) |
| CO (1) | CO2024003577A2 (enExample) |
| CR (1) | CR20240139A (enExample) |
| IL (1) | IL311175A (enExample) |
| JO (1) | JOP20240042A1 (enExample) |
| MX (1) | MX2024002753A (enExample) |
| PE (1) | PE20240895A1 (enExample) |
| TW (1) | TW202328187A (enExample) |
| WO (1) | WO2023034409A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024187057A2 (en) * | 2023-03-08 | 2024-09-12 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| CN116735864B (zh) * | 2023-08-15 | 2023-11-10 | 迦进生物医药(上海)有限公司 | 评估TfR1抗体血液安全性的试剂盒 |
| TW202517685A (zh) * | 2023-10-26 | 2025-05-01 | 美商百健Ｍａ公司 | 抗運鐵蛋白受體抗體及其用途 |
| WO2026076250A1 (en) * | 2024-10-03 | 2026-04-09 | Genentech, Inc. | Lipid nanoparticles for delivery to the cns from systemic administration |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| WO1991014452A1 (en) | 1990-03-27 | 1991-10-03 | The Salk Institute For Biological Studies | Method for inhibiting cell growth and compositions useful therefor |
| US5648469A (en) | 1992-04-20 | 1997-07-15 | The Salk Institute For Biological Studies | Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain |
| CA2561830C (en) | 2004-03-31 | 2013-05-21 | Adnagen Ag | Monoclonal antibodies with specificity for fetal erythroid cells |
| WO2005094364A2 (en) | 2004-03-31 | 2005-10-13 | Chimeric Technologies, Inc. | Iga antibody protein as a cytotoxic drug |
| PT1740616E (pt) | 2004-04-30 | 2012-03-23 | Inst Nat Sante Rech Med | Anticorpo anti-rtf |
| JP4824025B2 (ja) * | 2004-06-07 | 2011-11-24 | マクロジェニックス ウエスト，インコーポレイテッド | トランスフェリンレセプター抗体 |
| AU2005287406B2 (en) | 2004-07-26 | 2011-08-18 | Biogen Ma Inc. | Anti-CD154 antibodies |
| CA2600929A1 (en) | 2005-03-04 | 2006-09-14 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
| US7736647B2 (en) | 2005-06-15 | 2010-06-15 | Monoclonal Antibodies Therapeutics | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| FR2953841B1 (fr) | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| FR2959416B1 (fr) | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
| CA2818173C (en) | 2010-11-30 | 2022-05-03 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| CA2835603A1 (en) | 2011-05-09 | 2012-11-15 | Perseus Proteomics Inc. | Antibody capable of specifically recognizing transferrin receptor |
| TWI450727B (zh) | 2011-12-29 | 2014-09-01 | 財團法人工業技術研究院 | 抗人類輸鐵蛋白受體的單域抗體與其應用 |
| AU2013203422A1 (en) | 2012-01-06 | 2013-07-18 | Bioalliance C.V. | Anti-transferrin receptor antibodies and methods using same |
| HUE045144T2 (hu) | 2012-08-29 | 2019-12-30 | Hoffmann La Roche | Véragygát-shuttle |
| CA2893794C (en) | 2012-11-08 | 2021-11-09 | University Of Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
| EP2971047A4 (en) | 2013-03-15 | 2016-11-30 | Alper Biotech Llc | MONOCLONAL ANTIBODIES TO TRANSFERRIN AND TRANSFERRIN RECEPTOR ANTIGEN AND USES THEREOF |
| EP3594240B1 (en) | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| US9499628B2 (en) | 2013-06-14 | 2016-11-22 | Children's Hospital Medical Center | Method of boosting the immune response in neonates |
| EP3088518A4 (en) | 2013-12-25 | 2017-09-20 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
| CA2932547C (en) | 2014-01-06 | 2023-05-23 | F. Hoffmann-La Roche Ag | Monovalent blood brain barrier shuttle modules |
| US10508151B2 (en) * | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| BR112017023862A2 (pt) * | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| EA039366B1 (ru) | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| HUE057952T2 (hu) | 2015-06-24 | 2022-06-28 | Hoffmann La Roche | Anti-transzferrin receptor antitestek testreszabott affinitással |
| RU2737637C2 (ru) | 2015-07-22 | 2020-12-01 | Инатерис | Антитела против tfr и их применение при лечении пролиферативных и воспалительных расстройств |
| TWI873952B (zh) | 2015-10-02 | 2025-02-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| DK3473270T5 (da) | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| WO2018081720A1 (en) | 2016-10-29 | 2018-05-03 | Rhode Island Hospital | Glycosylated transferrin receptor 1 tumor antigen |
| KR102497564B1 (ko) | 2016-12-26 | 2023-02-07 | 제이씨알 파마 가부시키가이샤 | 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체 |
| CA3053381A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered polypeptides |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| EP3665194A4 (en) | 2017-08-10 | 2021-07-07 | Denali Therapeutics Inc. | AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS |
| AU2018378812B2 (en) | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| IL276327B2 (en) | 2018-02-05 | 2024-05-01 | Japan Chem Res | Method for delivering drug to muscle |
| US20210317226A1 (en) | 2018-08-02 | 2021-10-14 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating pompe disease |
| WO2020028836A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| IL280536B2 (en) | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2020028842A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| KR20210086601A (ko) | 2018-08-02 | 2021-07-08 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도 |
| AU2019314538B2 (en) | 2018-08-02 | 2025-03-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3829645A4 (en) | 2018-08-02 | 2022-05-18 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF PROGRESSIVE FIBRODYSPLASIA OSSIFIANS |
| EP3830130A4 (en) | 2018-08-02 | 2022-05-18 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating centronuclear myopathy |
| WO2020104479A1 (en) | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies |
| US20240148891A1 (en) | 2019-10-18 | 2024-05-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| AU2021206234A1 (en) | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3163608A1 (en) | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
| US20230103793A1 (en) * | 2020-01-31 | 2023-04-06 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| KR20230041760A (ko) | 2020-07-23 | 2023-03-24 | 다인 세라퓨틱스, 인크. | 항-트랜스페린 수용체 (tfr) 항체 및 그의 용도 |
| CA3202832A1 (en) | 2020-12-31 | 2022-07-07 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
-
2022
- 2022-08-31 WO PCT/US2022/042196 patent/WO2023034409A1/en not_active Ceased
- 2022-08-31 CR CR20240139A patent/CR20240139A/es unknown
- 2022-08-31 KR KR1020247010811A patent/KR20240107202A/ko active Pending
- 2022-08-31 US US17/900,161 patent/US11827702B2/en active Active
- 2022-08-31 CA CA3230796A patent/CA3230796A1/en active Pending
- 2022-08-31 IL IL311175A patent/IL311175A/en unknown
- 2022-08-31 MX MX2024002753A patent/MX2024002753A/es unknown
- 2022-08-31 EP EP22783097.3A patent/EP4396231A1/en active Pending
- 2022-08-31 PE PE2024000361A patent/PE20240895A1/es unknown
- 2022-08-31 JP JP2024513785A patent/JP2024534880A/ja active Pending
- 2022-08-31 TW TW111132949A patent/TW202328187A/zh unknown
- 2022-08-31 AU AU2022340568A patent/AU2022340568A1/en active Pending
-
2023
- 2023-10-19 US US18/490,319 patent/US20240158494A1/en active Pending
-
2024
- 2024-02-29 JO JOJO/P/2024/0042A patent/JOP20240042A1/ar unknown
- 2024-03-01 CL CL2024000642A patent/CL2024000642A1/es unknown
- 2024-03-21 CO CONC2024/0003577A patent/CO2024003577A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202328187A (zh) | 2023-07-16 |
| CR20240139A (es) | 2024-06-14 |
| PE20240895A1 (es) | 2024-04-24 |
| WO2023034409A1 (en) | 2023-03-09 |
| US20230131379A1 (en) | 2023-04-27 |
| AU2022340568A1 (en) | 2024-03-28 |
| CO2024003577A2 (es) | 2024-06-27 |
| CA3230796A1 (en) | 2023-03-09 |
| KR20240107202A (ko) | 2024-07-08 |
| JOP20240042A1 (ar) | 2024-02-29 |
| JP2024534880A (ja) | 2024-09-26 |
| MX2024002753A (es) | 2024-05-20 |
| US20240158494A1 (en) | 2024-05-16 |
| US11827702B2 (en) | 2023-11-28 |
| IL311175A (en) | 2024-04-01 |
| EP4396231A1 (en) | 2024-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000642A1 (es) | Anticuerpos del receptor antitransferrina y usos de los mismos | |
| CL2023003607A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| CO2019007288A2 (es) | Anticuerpos anti-ox40 y sus usos | |
| CO2019003154A2 (es) | Anticuerpos anti-pd-1 y sus usos | |
| MX2020014243A (es) | Neoantigenos y usos de los mismos. | |
| PE20221894A1 (es) | Agentes de union a ilt y metodos para su uso | |
| MX2020013977A (es) | Proteínas quiméricas transmembrana y usos de las mismas. | |
| CO2019012473A2 (es) | Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos | |
| CL2018000358A1 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
| CL2022001622A1 (es) | Agentes de unión a ilt3 y métodos de uso de los mismos | |
| BR112022025221A2 (pt) | Sistemas de expressão de baculovírus | |
| ECSP11011344A (es) | Nuevos anticuerpos anti-?5?1 y sus usos | |
| CL2016001256A1 (es) | Composiciones y métodos para anticuerpos dirigidos factor de p (divisional de sol. n° 1640-14). | |
| CL2022003684A1 (es) | Agentes de unión a lair-1 y métodos para su uso | |
| MX2023009238A (es) | Nuevos anticuerpos anti-cd24. | |
| CU20180047A7 (es) | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación | |
| MX2021004925A (es) | Variantes de adn-polimerasa modificadas. | |
| CO2025007355A2 (es) | Anticuerpo anti-trem2 y usos del mismo | |
| CO2023014622A2 (es) | Conjugados de anticuerpo-fármaco anti-c-met | |
| MX2021011887A (es) | Receptores de antigeno quimerico humanizados anti-claudin 18.2 y usos de los mismos. | |
| MX2021014973A (es) | Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. | |
| PE20210634A1 (es) | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos | |
| CO2024007674A2 (es) | Anticuerpo anti-trem2 y usos del mismo | |
| CL2024003418A1 (es) | Proteínas de fusión hmpv pre-fusión estabilizadas | |
| CO2022014878A2 (es) | Anticuerpos anti-factor bb del complemento humanizados y usos de los mismos |